AstraZeneca and Merck today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for Lynparza in metastatic breast cancer. The trial compared Lynparza ... read more
AstraZeneca and Merck today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for Lynparza in metastatic breast cancer. The trial compared Lynparza ... read more
Merck today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Study... read more
DNAtix has completed the first Proof Of Concept (POC) test by transferring the complete genome sequence of a virus - Enterobacteria phage phiX174 sensu lato - over the Ethereum Blockchain. The... read more
NGM Bio today announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological measures of disease in nonalcoholic... read more
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,